Maya Khalil, MD

No bio available.

Financial relationships

  • Attribution:
    Other
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Other - Jounce Therapeutics
    Topic:
    Principal or sub investigator on clinical trial
    Date added:
    06/04/2024
    Date updated:
    06/04/2024
    Relationship end date:
    12/31/2027
  • Attribution:
    Other
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Other - Innate Pharma
    Topic:
    Principal or sub investigator on clinical trial
    Date added:
    06/04/2024
    Date updated:
    06/04/2024
    Relationship end date:
    12/31/2027
  • Attribution:
    Other
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Advenchen Pharmaceuticals, LLC
    Topic:
    Principal or sub investigator on clinical trial
    Date added:
    06/04/2024
    Date updated:
    06/04/2024
    Relationship end date:
    12/31/2027
  • Attribution:
    Other
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Other - Xencor
    Topic:
    Principal or sub investigator on clinical trial
    Date added:
    06/04/2024
    Date updated:
    06/04/2024
    Relationship end date:
    12/31/2027
  • Attribution:
    Other
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Merck & Co., Inc.
    Topic:
    Principal or sub investigator on clinical trial
    Date added:
    06/04/2024
    Date updated:
    06/04/2024
    Relationship end date:
    12/31/2027
  • Attribution:
    Other
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Other - Debiopharm Group
    Topic:
    Principal or sub investigator on clinical trial
    Date added:
    06/04/2024
    Date updated:
    06/04/2024
    Relationship end date:
    12/31/2027
  • Attribution:
    Other
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Taiho Pharmaceuticals Co., Ltd.
    Topic:
    Principal or sub investigator on clinical trial
    Date added:
    06/04/2024
    Date updated:
    06/04/2024
    Relationship end date:
    12/31/2027
  • Attribution:
    Other
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Other - Summit
    Topic:
    Principal or sub investigator on clinical trial
    Date added:
    06/04/2024
    Date updated:
    06/04/2024
    Relationship end date:
    12/31/2027
  • Attribution:
    Other
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Regeneron Pharmactcls
    Topic:
    Principal or sub investigator on clinical trial
    Date added:
    06/04/2024
    Date updated:
    06/04/2024
    Relationship end date:
    12/31/2027
  • Attribution:
    Other
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Takeda Pharmaceuticals North America, Inc.
    Topic:
    Principal or sub investigator on clinical trial
    Date added:
    06/04/2024
    Date updated:
    06/04/2024
    Relationship end date:
    12/31/2027

Pages

Return to Sept. 27-28, 2024 - Symposium for Evolving Therapies and Drug Development in Oncology